Evidence map›Paper›PMID 37862630›Full record

ArticleThe Journal of family practice2023

Updates in the Management of Erosive Esophagitis.

John E Pandolfino, Stuart J Spechler, Rena Yadlapati

Abstract read
In one paragraph

Article in The Journal of family practice, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. GERD: Latest update on acid-suppressant drugs.Current research in pharmacology and drug discovery · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

John E Pandolfino
Stuart J Spechler
Rena Yadlapati

Funding

Targeting Hypervigilance and Autonomic Arousal: the Psycho-physiologic Model of GERDR01DK092217 · NIDDK · NORTHWESTERN UNIVERSITY AT CHICAGO · PI JOHN E PANDOLFINO · 2012 to 2026
$5.0M
The MVP Trial: A Randomized Controlled Trial of Mechanism Guided vs PPI Strategy for Laryngopharyngeal RefluxR01DK139089 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Rena Hiren Yadlapati · 2024 to 2026
$2.0M
Mechanism Guided Therapy for Laryngopharyngeal RefluxK23DK125266 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI YADLAPATI, RENA HIREN · 2021 to 2025
$963k
NIDDK NIH HHS K23 DK125266NIDDK NIH HHS R01 DK092217NIDDK NIH HHS R01 DK139089
6 · The paper itself

Abstract

Upon completion of this activity, participants will:Have increased knowledge regarding the Mechanistic differences between proton pump inhibitors (PPIs) and potassium-competitive acid blockers (PCABs) Evidence comparing PPIs with PCABs for the treatment of GERD and EE Have greater competence related to Selecting evidence-based treatments for EE.

Indexed as

EsophagitisGastroesophageal RefluxPeptic UlcerHumansProton Pump InhibitorsProton Pump Inhibitors

Identifiers

PMID37862630
PMCPMC12168557

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.